Clinical Trial Update: Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing Iberogast for efficacy and safety in irritable bowel syndrome compared with placebo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• IBEROGAST

Snippet

Sponsor: Bayer | Conditions: Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED